Meeder Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Meeder Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-51	Closed	-$3K	–	1454
2022 Q3	$3K	Buy	51 +9	+21%	+$529	﹤0.01%	1721
2022 Q2	$2K	Buy	42 +29	+223%	+$1.65K	﹤0.01%	1898
2022 Q1	$1K	Hold	13	–	–	﹤0.01%	2202
2021 Q4	$1K	Sell	13 -397	-97%	-$36.7K	﹤0.01%	1029
2021 Q3	$35K	Buy	410 +73	+22%	+$5.65K	﹤0.01%	1206
2021 Q2	$27K	Buy	337 +148	+78%	+$12.3K	﹤0.01%	1355
2021 Q1	$18K	Buy	189 +58	+44%	+$5.48K	﹤0.01%	1440
2020 Q4	$8K	Sell	131 -5,556	-98%	-$317K	﹤0.01%	1061
2020 Q3	$338K	Buy	5,687 +428	+8%	+$29.2K	0.02%	476
2020 Q2	$367K	Sell	5,259 -4,673	-47%	-$296K	0.02%	448
2020 Q1	$450K	Buy	+9,932	New	+$563K	0.04%	356
2018 Q4	–	Sell	-298	Closed	-$51K	–	1758
2018 Q3	$51K	Buy	298 +118	+66%	+$17.8K	﹤0.01%	776
2018 Q2	$23.2K	Buy	+180	New	+$20.1K	﹤0.01%	931
2018 Q1	–	Sell	-51	Closed	-$4K	–	1654
2017 Q4	$4K	Buy	51 +6	+13%	+$520	﹤0.01%	1364
2017 Q3	$4K	Buy	+45	New	+$3.56K	﹤0.01%	1323
2016 Q3	–	Sell	-2,403	Closed	-$179K	–	856
2016 Q2	$179K	Buy	+2,403	New	+$178K	0.02%	582

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's LGND Position: Q4 2022 in Review

Meeder Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 51 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in LGND in Q2 2016 and held it in 16 quarters. The position peaked at $450K in Q1 2020. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Meeder Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 51 Ligand Pharmaceuticals shares in Q4 2022, an estimated $3K.
Meeder Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 16 quarters.
Meeder Asset Management's Ligand Pharmaceuticals position peaked at $450K in Q1 2020.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.